Us Bancorp \De\ Ultragenyx Pharmaceutical Inc. Transaction History

Us Bancorp \De\

$75.6 Billion
Q4 2024

A detailed history of Us Bancorp \De\ transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 3,534 shares of RARE stock, worth $136,730. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,534

Previous 4,149 14.82%

Holding current value

$136,730

Previous $230,000 35.65%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 05, 2025	SELL	$42.07 - $57.72 $25,873 - $35,497	-615 Reduced 14.82%	3,534 $148,000
Q3 2024 Oct 28, 2024	SELL	$40.21 - $59.36 $117,252 - $173,093	-2,916 Reduced 41.27%	4,149 $230,000
Q2 2024 Aug 06, 2024	SELL	$37.42 - $51.61 $2,918 - $4,025	-78 Reduced 1.09%	7,065 $290,000
Q1 2024 May 07, 2024	BUY	$43.02 - $53.69 $16,777 - $20,939	390 Added 5.78%	7,143 $333,000
Q4 2023 Feb 09, 2024	BUY	$31.73 - $49.19 $7,202 - $11,166	227 Added 3.48%	6,753 $322,000
Q3 2023 Nov 03, 2023	SELL	$34.92 - $46.66 $23,151 - $30,935	-663 Reduced 9.22%	6,526 $232,000
Q2 2023 Aug 09, 2023	BUY	$37.35 - $52.15 $169,456 - $236,604	4,537 Added 171.08%	7,189 $331,000
Q1 2023 May 09, 2023	SELL	$36.99 - $48.71 $13,723 - $18,071	-371 Reduced 12.27%	2,652 $106,000
Q4 2022 Feb 13, 2023	SELL	$33.72 - $46.33 $184,043 - $252,869	-5,458 Reduced 64.36%	3,023 $140,000
Q3 2022 Oct 27, 2022	BUY	$39.96 - $66.14 $7,992 - $13,228	200 Added 2.42%	8,481 $351,000
Q2 2022 Aug 01, 2022	SELL	$45.8 - $85.4 $15,113 - $28,182	-330 Reduced 3.83%	8,281 $495,000
Q1 2022 May 11, 2022	BUY	$62.2 - $84.4 $68,233 - $92,586	1,097 Added 14.6%	8,611 $625,000
Q4 2021 Feb 11, 2022	SELL	$73.71 - $87.86 $660,810 - $787,664	-8,965 Reduced 54.4%	7,514 $631,000
Q3 2021 Nov 10, 2021	BUY	$77.92 - $102.4 $55,790 - $73,318	716 Added 4.54%	16,479 $1.49 Million
Q2 2021 Aug 05, 2021	SELL	$92.19 - $115.71 $371,525 - $466,311	-4,030 Reduced 20.36%	15,763 $1.5 Million
Q1 2021 Apr 28, 2021	BUY	$106.9 - $167.73 $519,320 - $814,832	4,858 Added 32.53%	19,793 $2.25 Million
Q4 2020 Feb 04, 2021	BUY	$84.4 - $177.39 $904,346 - $1.9 Million	10,715 Added 253.91%	14,935 $2.07 Million
Q3 2020 Nov 10, 2020	BUY	$72.98 - $90.0 $300,020 - $369,990	4,111 Added 3771.56%	4,220 $346,000
Q2 2020 Aug 07, 2020	BUY	$46.91 - $78.22 $2,908 - $4,849	62 Added 131.91%	109 $9,000
Q4 2019 Feb 04, 2020	SELL	$36.08 - $45.83 $2,020 - $2,566	-56 Reduced 54.37%	47 $2,000
Q3 2019 Nov 08, 2019	SELL	$42.5 - $63.11 $2,720 - $4,039	-64 Reduced 38.32%	103 $4,000
Q1 2019 May 08, 2019	BUY	$39.87 - $69.36 $4,186 - $7,282	105 Added 169.35%	167 $11,000
Q4 2018 Feb 13, 2019	SELL	$38.89 - $77.3 $2,761 - $5,488	-71 Reduced 53.38%	62 $3,000
Q2 2018 Aug 08, 2018	BUY	$48.54 - $85.31 $2,524 - $4,436	52 Added 64.2%	133 $10,000
Q1 2018 May 08, 2018	BUY	$44.33 - $58.52 $2,526 - $3,335	57 Added 237.5%	81 $4,000
Q4 2017 Feb 02, 2018	BUY	$43.54 - $57.32 $914 - $1,203	21 Added 700.0%	24 $1,000
Q3 2017 Nov 13, 2017	BUY	$49.79 - $66.32 $149 - $198	3	3 $0

Others Institutions Holding RARE

# of Institutions

344

Shares Held

84.3M

Call Options Held

675K

Put Options Held

846K

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $2.71B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account